Standout Papers
- A potent specific pure antiestrogen with clinical potential. (1991)
Citation Impact
Citing Papers
De novo protein synthesis is required for the activation-induced cytidine deaminase function in class-switch recombination
2003 StandoutNobel
SuFEx-enabled, agnostic discovery of covalent inhibitors of human neutrophil elastase
2019 StandoutNobel
Targeted cell killing by reconstituted caspases
2007 StandoutNobel
Estrogen Dendrimer Conjugates that Preferentially Activate Extranuclear, Nongenomic Versus Genomic Pathways of Estrogen Action
2005
Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation
2003
Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition
2004
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Estradiol Hypersensitivity and Mitogen-Activated Protein Kinase Expression in Long-Term Estrogen Deprived Human Breast Cancer Cellsin Vivo1
2000
Functional characteristics of a novel murine estrogen receptor-beta isoform, estrogen receptor-beta 2
2000
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Transcriptional regulator of programmed cell death encoded by Caenorhabditis elegans gene ces-2
1996 StandoutNatureNobel
The genetic regulation of apoptosis
1995
The discovery of receptor tyrosine kinases: targets for cancer therapy
2004
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Bone marrow cells regenerate infarcted myocardium
2001 StandoutNature
Expanding functional diversity of the coactivators
2005
The biology and management of non-small cell lung cancer
2018 StandoutNature
Dicing with death: dissecting the components of the apoptosis machinery
1994
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)
2010
Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells
2003
Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions
2008
EGF–ERBB signalling: towards the systems level
2006 Standout
A mediator required for activation of RNA polymerase II transcription in vitro
1991 StandoutNatureNobel
Tyrosine kinases as targets in cancer therapy – successes and failures
2003
The biochemistry of apoptosis
2000 StandoutNature
Apoptotic DNA Fragmentation
2000
Historical perspective on hormonal therapy of advanced breast cancer
2002
Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with Apoptosis
1998 Standout
A Good Drug Made Better: The Fulvestrant Dose-Response Story
2014
Chapter 15 Simultaneous Measurement of Cell Cycle and Apoptotic Cell Death
1998
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
1998 Standout
Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.
2003
Targeting RAS signalling pathways in cancer therapy
2003 Standout
Mediators of Chronic Obstructive Pulmonary Disease
2004
Gefitinib — a novel targeted approach to treating cancer
2004
Endocrine-responsive breast cancer and strategies for combating resistance
2002
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
1995 StandoutNature
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators
2005
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Differential SERM Effects on Corepressor Binding Dictate ERα Activity in Vivo
2003
The Fas Death Factor
1995 StandoutScience
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
2010
Regulation of Cre Recombinase Activity by Mutated Estrogen Receptor Ligand-Binding Domains
1997
Molecular characterization of mitochondrial apoptosis-inducing factor
1999 StandoutNature
The Mechanism of ICI 164,384 Antiestrogenieity Involves Rapid Loss of Estrogen Receptor in Uterine Tissue
1991
Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials
2004
Steroid hormone receptors compete for factors that mediate their enhancer function
1989
The Crystal Structure of Yeast Fatty Acid Synthase, a Cellular Machine with Eight Active Sites Working Together
2007 StandoutNobel
A novel mediator between activator proteins and the RNA polymerase II transcription apparatus
1990 StandoutNobel
Estrogen rapid action via protein complex formation involving ERα and Src
2005
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
2005
Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective
2004
Structural Insights into the Mode of Action of a Pure Antiestrogen
2001
Apoptosis in the Failing Human Heart
1997 Standout
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Glutamate-induced neuronal death: A succession of necrosis or apoptosis depending on mitochondrial function
1995 Standout
Commitment to cell death measured by loss of clonogenicity is separable from the appearance of apoptotic markers
1998
Dual modulation of cell survival and cell death by β 2 -adrenergic signaling in adult mouse cardiac myocytes
2001 StandoutNobel
Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)*
2001
Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene.
1993 StandoutNobel
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
NUC-1, aCaenorhabditis elegansDNase II homolog, functions in an intermediate step of DNA degradation during apoptosis
2000 StandoutNobel
17β-Estradiol reduces vasoconstriction in endothelium-denuded rat aortas through inducible NOS
1998
BindingDB Entry 50022499: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
2025
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
RNA–protein analysis using a conditional CRISPR nuclease
2013 StandoutNobel
The Bcl-2 Protein Family: Arbiters of Cell Survival
1998 StandoutScience
Pacing-Induced Heart Failure in Dogs Enhances the Expression of p53 and p53-Dependent Genes in Ventricular Myocytes
1998
Cell-free reconstitution of Fas-, UV radiation- and ceramide-induced apoptosis.
1995
Fulvestrant (Faslodex®)—How to Make a Good Drug Better
2007
Ligand-dependent interactions of coactivators steroid receptor coactivator-1 and peroxisome proliferator-activated receptor binding protein with nuclear hormone receptors can be imaged in live cells and are required for transcription
2000 StandoutNobel
Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
2002
Coactivator and Corepressor Regulation of the Agonist/Antagonist Activity of the Mixed Antiestrogen, 4-Hydroxytamoxifen
1997
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
2000
Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element.
1993
The NEDD8 Pathway Is Required for Proteasome-Mediated Degradation of Human Estrogen Receptor (ER)-α and Essential for the Antiproliferative Activity of ICI 182,780 in ERα-Positive Breast Cancer Cells
2003
Abnormal Vascular Function and Hypertension in Mice Deficient in Estrogen Receptor β
2002 StandoutScienceNobel
Selective Estrogen Receptor Modulators
2004
Cell nucleus and DNA fragmentation are not required for apoptosis.
1994
Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens.
1995
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
1999 Standout
Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance
2004
Direct Visualization of the Human Estrogen Receptor α Reveals a Role for Ligand in the Nuclear Distribution of the Receptor
1999
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition
2002
Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct.
1996 StandoutNobel
Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.
1996
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
The Caenorhabditis elegans mucolipin-like gene cup-5 is essential for viability and regulates lysosomes in multiple cell types
2002 StandoutNobel
Human Bak Induces Cell Death in Schizosaccharomyces pombe with Morphological Changes Similar to Those with Apoptosis in Mammalian Cells
1997
Targeting Fatty Acid Synthase in Breast and Endometrial Cancer: An Alternative to Selective Estrogen Receptor Modulators?
2006
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial
2002
Molecular correlates of gefitinib responsiveness in human bladder cancer cells
2007
Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.
2003
The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis
1997 StandoutScience
Identification of simple arylfluorosulfates as potent agents against resistant bacteria
2021 StandoutNobel
Caspases: the executioners of apoptosis
1997 Standout
Ultrafast Dynamics of Flavins in Five Redox States
2008 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Recruitment of Histone Deacetylase 4 to the N-Terminal Region of Estrogen Receptor α
2005
Bax- and Bak-induced cell death in the fission yeast Schizosaccharomyces pombe.
1997
Mitochondria and Apoptosis
1998 StandoutScience
Mammalian Caspases: Structure, Activation, Substrates, and Functions During Apoptosis
1999 Standout
Occurrence and Properties of a Prostaglandin F2α Receptor in Bovine Corpora Lutea
1975 StandoutNobel
Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones.
1996
Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition
2002
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
2003
Human vascular smooth muscle cells contain functional estrogen receptor.
1994
Fluorine in medicinal chemistry: A review of anti-cancer agents
2006
Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor.
1992
High rate of CAD gene amplification in human cells deficient in MLH1 or MSH6
2001 StandoutNobel
hMutSα- and hMutLα-dependent phosphorylation of p53 in response to DNA methylator damage
1999 StandoutNobel
A cell nanoinjector based on carbon nanotubes
2007 StandoutNobel
Involvement of the Mismatch Repair System in Temozolomide-Induced Apoptosis
1998
Estrogen Receptor Modulators: Identification and Structure−Activity Relationships of Potent ERα-Selective Tetrahydroisoquinoline Ligands
2003
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
2002
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
2006 StandoutScience
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
1998
Estrogen inhibits the vascular injury response in estrogen receptor β-deficient female mice
1999 StandoutNobel
Works of A. E. Wakeling being referenced
Modulation of Epidermal Growth Factor Receptor in Endocrine‐Resistant, Estrogen‐Receptor‐Positive Breast Cancer
2002
Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.
2001
Circumvention of tamoxifen resistance by the pure anti‐estrogen ICI 182, 780
1993
A comparative study of the interaction of oestradiol and the steroidal pure antioestrogen, ICI 164,384, with the molybdate-stabilized oestrogen receptor
1990
Pure Antiestrogens The Most Important Advance in the Endocrine Therapy of Breast Cancer since 1896?a
1996
Novel antioestrogens without partial agonist activity
1988
Responses to Pure Antiestrogens (ICI 164384, ICI182780) in Estrogen‐Sensitive and‐Resistant Experimental and Clinical Breast Cancera
1995
Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.
2002
Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer
1996
Biology and mode of action of pure antioestrogens
1988
Effects of a non-steroidal pure antioestrogen, ZM 189,154, on oestrogen target organs of the rat including bones
1994
Comparison of the Effects of a Pure Steroidal antiestrogen With Those of Tamoxifen in a Model of Human Breast Cancer
1995
Novel Pure Antiestrogens. Mode of Action and Therapeutic Prospects
1990
Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer
2004
Similarities and distinctions in the mode of action of different classes of antioestrogens.
2000
Epidermal growth factor receptor tyrosine kinase inhibitors
2002
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
2004
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells
2004
Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines
1996
Oestrogen receptor expression in human breast cancer during long-term fulvestrant treatment
2004
Prostaglandin specific binding in the rabbit oviduct
1973
A potent specific pure antiestrogen with clinical potential.
1991 Standout
The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro
2003
Biology and mode of action of pure antioestrogens.
1988
Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation.
1993
New targets for therapeutic attack
1997
Prospects for combining hormonal and nonhormonal growth factor inhibition.
2001
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
2001
Non-steroidal antioestrogens—Receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells
1984
Oestrogen receptor expression in human breast cancer during long-term fulvestrant treatment
2004
Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle.
1989
ZD1839, AN EPIDERMAL GROWTH FACTOR TYROSINE KINASE INHIBITOR SELECTED FOR CLINICAL DEVELOPMENT
1997